LMWH treatment. LMWF did not prolong the bleeding time or decrease platelet aggregation. Conclusions: LMWF appeared to be more effective than LMWH for preventing arterial thrombosis in this experimental model. LMWF also had a lower hemorrhagic risk than LMWH.
. As previously described for heparins [3, 4] , fucoidan induces tissue factor pathway inhibitor (TFPI) release from cultured human umbilical vein endothelial cells, which may also contribute to its antithrombotic effect [5] . A LMW fucoidan (LMWF) can be obtained by acid hydrolysis (MW 8 kDa) or by radical depolymerization (MW 7 kDa) [1] . The antithrombotic activity of these LMWFs have been compared with LMWH in the Wessler rabbit model [6, 7] . Thrombus formation was inhibited by 80% (ED 80 ) by 20 mg/kg of 8-kDa LMWF and by 200 antiXa IU of LMWH. When used at these doses, LMWF did not prolong the thrombin clotting time (TCT) or increase anti-Xa activity, contrary to LMWH. Both drugs slightly prolonged the activated partial thromboplastin time (APTT). The 7-kDa LMWF fraction, corresponding to that used in our study, had even higher antithrombotic activity, with an ED 80 of 7.5 mg/kg and a total inhibition of thrombus formation at 10 mg/kg. Neither dose augments the APTT or TCT [7] . These data suggest that LMWF would carry a lower hemorrhagic risk than LMWH [6, 7] . We recently developed a model of arterial thrombosis involving local stimulation of endothelial apoptosis with staurosporine, leading to endothelial denudation, thus reproducing the 2 main components of plaque erosion in humans [8] . Here, we compared the antithrombotic and anticoagulant effects of LMWF and LMWH in this experimental model.
Materials and Methods
Materials LMWH [enoxaparin: molecular mass 5,000 g/mol; anticoagulant activity: 10,000 anti-Xa IU/ml (100 mg/ml)] was obtained from Sanofi Aventis, France.
LMWF was obtained from IFREMER, Nantes, France, and produced by a radical depolymerization process [1] .
Determination of Appropriate LMWF and LMWH Doses
Dose-effect curves were constructed with LMWF (7.5, 10 and 15 mg/kg) and LMWH (1, 2.5, 5, 10 and 15 mg/kg) in order to determine the optimal doses for the in vivo study. Four animals were used for each dose.
Treatment
Control animals (n = 6) received twice-daily subcutaneous injections of saline solution, from the day before arterial thrombosis induction until sacrifice. The treatment groups (n = 6 each) received LMWF or LMWH in identical conditions.
Experimental Model of Arterial Thrombosis
The study conformed to US National Institutes of Health guidelines and was approved by our local animal experimentation committee. Arterial thrombosis was induced in the femoral arteries of male New Zealand White rabbits weighing 3-4 kg, by in situ induction of endothelial apoptosis with staurosporine, as previously described [8] . The animals (n = 18) were anesthetized with a combination of xylazine (5 mg/kg) and ketamine (35 mg/ kg). The 2 arteries were ligatured to isolate a segment 1 cm long that was punctured proximally with a 27-gauge needle and injected with staurosporine (10 -5 M ). After 30 min of incubation, the femoral segments were washed twice with saline and the ligatures were released.
Assessment of Vessel Thrombosis and Immunochemistry
The animals were screened for thrombosis by angiography and histology 3 days after induction of endothelial apoptosis. Thrombus was defined histologically by the presence of an adherent intraluminal material partially or totally occluding the lumen, as previously described [8] . Thrombosis was scored as follows: 0, no thrombosis; 1, less than 50% of the vessel lumen; 2, between 50 and 75%, and 3, more than 75%.
Endothelial denudation was evaluated by staining with a monoclonal anti-CD31 antibody (Dako, Trappes, France). Apoptotic cells were detected in situ with the TUNEL method (Apoptag kit, Oncor, Gaithersburg, Md., USA). Apoptosis in the endothelial lining was scored semiquantitatively by 2 blinded observers, as follows: 0, barely detectable or no staining; 1, weak staining; 2, moderate focal staining, and 3, strong diffuse staining [8] . Areas with no endothelial cell lining (negative CD31 staining) were scored as 3. The percentage of endothelial cells (total and apoptotic) remaining after staurosporine treatment was determined as previously described [8] .
Sections were stained with a monoclonal anti-rabbit tissue factor (TF) antibody (American Diagnostica, Greenwich, Conn., USA) and with goat polyclonal antibodies against P-and E-selectin (Santa Cruz Biotechnology, Santa Cruz, Calif., USA) in order to evaluate TF and selectin expression, respectively. TF expression was scored semiquantitatively by 2 blinded observers, as follows: 0, barely detectable or no staining; 1, weak staining; 2, moderate focal staining, and 3, strong diffuse staining, as previously described [9] .
Measurement of Anticoagulant Activity
Three blood samples from each animal were collected in 3.8% sodium citrate in order to determine anticoagulant activity at baseline, 1 h after the second subcutaneous injection and 1 h after the final (8th) injection. Platelet-poor plasma was obtained by 2 centrifugation steps at 1,000 g for 10 min at 20 ° C and was stored at -80 ° C until use. In the preliminary dose-finding study, blood samples were collected 1 h after the first injection.
Anticoagulant activity was determined with a STAR analyser (Stago, Gennevilliers, France) in terms of the APTT (Automated APTT, BioMerieux, Durham, N.C., USA) and the TCT (Sigma Aldrich, Saint-Louis, Mo., USA). Anti-Xa activity was determined by commercial chromogenic assay (STA Rotachrom Heparin 8, Stago).
Measurement of Bleeding Time and Platelet Aggregation
Bleeding time and platelet aggregation were evaluated 1 h after the final injection in each group. The bleeding time (in seconds) was measured at the ear, as previously described [10, 11] .
Citrated blood samples were centrifuged at 225 g for 20 min at 25 ° C to recover platelet-rich plasma and were then centrifuged at 2,000 g for 10 min at 25 ° C to recover platelet-poor plasma. The platelet-rich plasma was adjusted to 200-250 ! 10 6 platelets/ml with homologous platelet-poor plasma. Platelets were stimulated with 50 n M ␥ -thrombin (a generous gift from M. Jeandrot-Perrus and M.C. Guillin), and aggregation was assessed with a platelet aggregometer (Regulest, Florange, France). ␥ -Thrombin (a product of limited ␣ -thrombin proteolysis) is not able to cleave fibrinogen into fibrin, like ␣ -thrombin, but induces platelet aggregation. It was used as an agonist, as LMWF has anti-thrombin activity. Aggregation was expressed as the maximum percentage change in light transmittance from baseline, with platelet-poor plasma as reference.
Measurement of Plasma TFPI Activity
TFPI activity was measured in each animal at baseline and 1 h after the second injection. TFPI activity in plasma was determined with a 2-step colorimetric assay, as previously described, with modifications [12] . All reagents were obtained from American Diagnostica. Briefly, in the first step, a 1/40 dilution of the test sample was incubated with human factor VIIa and 20 ng/ml rabbit recombinant TF complex. In the second step, a saturating concentration of human factor X was added to the reaction mixture as a substrate for residual factor VIIa/TF catalytic activity; the amount of factor Xa thus generated was determined with the specific chromogenic substrate Spectrozyme Xa by measuring absorbance at 405 nm. Linear calibration curves were obtained with dilutions of pooled rabbit plasma. Results are expressed as the percentage of TFPI activity in this pooled rabbit plasma.
Statistical Analysis
Parametric data are expressed as means 8 SD. Nonparametric data are expressed as medians and upper and lower quartiles. Scores for thrombosis, apoptosis, endothelial denudation and TF expression were averaged for the 2 arteries in each animal, and the mean values for the 6 animals in each group were used for statistical analysis. Interobserver variability for semiquantitative TF expression and apoptosis was determined by calculating concordance and the score. Thrombotic activity was analyzed with Fisher's exact test by comparing the numbers of animals in each group with a thrombus in either artery. Two-way ANOVA or the Kruskal-Wallis test was used to compare parametric and nonparametric data among the 3 groups of animals. If a global difference was found, a least-squares difference test for multiple comparisons or the Mann-Whitney test, as appropriate, was used to identify pairwise differences between groups. Values were considered significantly different with p ! 0.05.
Results

Choice of LMWF and LMWH Doses
APTT was not significantly increased by 10 mg/kg LMWF, but rose 2 fold after injection of 15 mg/kg ( fig. 1 a) . TCT and anti-Xa activity were not significantly affected, whatever the LMWF dose ( fig. 1 b, c) . LMWH doses from 5 to 15 mg/kg markedly increased the APTT, the TCT and anti-Xa activity to levels compatible with hemorrhagic adverse effects ( fig. 1 a-c) . At 2.5 mg/kg, LMWH induced a 2-fold increase in APTT. We thus chose to inject the doses that doubled the APTT (2.5 and 15 mg/kg LMWH and LMWF, respectively).
Incidence of Thrombosis
Thrombosis occurred in 5 of the 6 control animals ( fig. 2 a, d ). In the LMWH group, thrombosis occurred in 4 of the 6 animals ( fig. 2 b, d) , and in the LMWF group, thrombosis occurred in only 1 of the 6 animals ( fig. 2 c, d). The difference between the LMWF and control groups was significant (p = 0.03; fig. 2 d) . The semiquantitative thrombosis score was significantly lower in the LMWF group than in the control and LMWH groups ( fig. 2 e) . Staurosporine-treated arteries exhibited large areas of endothelial denudation ( fig. 3 a-c) , and the remaining endothelial cells were mostly apoptotic ( fig. 3 e-g ). Interobserver concordance was 94%, and the score was 0.88, indicating excellent agreement. In addition, the endothelial denudation and apoptosis scores were similar in the 3 groups, indicating good reproducibility of endothelial apoptosis induction ( fig. 3 i, j) . P-selectin expression in the remaining endothelial cells was similar in the 3 groups (data not shown). E-selectin was not detected in any group (data not shown). Finally, leukocytes were detected mostly within the thrombus and in very small numbers in the media of denuded arteries in the 3 groups (data not shown).
Anticoagulant Activity
No significant difference in the APTT was observed at baseline ( fig. 4 a) . The APTT increased similarly 1 h after the second and final injections in the LMWH and LMWF groups ( fig. 4 a) .
The TCT values were similar at baseline ( fig. 4 b) . One hour after the second and last injections, the TCT rose significantly in the LMWH group ( 1 120 s) relative to the control and LMWF groups. The TCT was not significantly different in the LMWF and control groups 1 h after the second and last injections ( fig. 4 b) . Finally, anti-Xa activity was similar at baseline ( fig. 4 c) . One hour after the second and the final injections, antiXa activity was significantly higher in the LMWH group than in the control (p ! 0.0001) and LMWF groups (p ! 0.0001; fig. 4 c) . Anti-Xa activity was similar in the control and LMWF groups ( fig. 4 c) .
The platelet counts were similar in the 3 groups at all time points. The hemoglobin level fell in all 3 groups, likely owing to surgery and sampling (data not shown). 
Bleeding Time and Platelet Aggregation Induced by ␥ -Thrombin
Effect of LMWF on the TF Pathway
In the control and LMWH groups, strong TF expression was observed, mainly in the media, but also in remaining endothelial cells and within the thrombus ( fig. 5 a, b) . In contrast, TF expression was very low in the media in the LMWF group ( fig. 5 c) . Moreover, TF expression was significantly lower in the LMWF group than in the control and LMWH groups ( fig. 5 d) . Interobserver concordance was 86%, and the score was 0.72, indicating substantial agreement.
LMWF induced a significant increase in TFPI activity ( fig. 5 e) 1 h after the second injection compared with baseline. No significant difference in TFPI activity was observed in the control group or the LMWH group 1 h after the second injection ( fig. 5 e) .
Discussion
Antithrombotic Activity of LMWF LMWHs are widely used in the treatment of acute coronary syndromes. They are preferred to UF heparin because they have more predictable bioavailability and pharmacokinetics and do not require routine monitoring [13] . Here, we compared the antithrombotic and anticoagulant activity of LMWF and LMWH in an experimental model of arterial thrombosis due to endothelial apoptosis. This model reproduces the mechanisms of thrombotic plaque erosion responsible for 30-40% of cases of arterial thrombosis, particularly in women [8] . The incidence of thrombosis was particularly low in LMWF-treated animals and significantly lower than in control animals. Moreover, the severity of thrombosis was significantly lower in the LMWF group than in the control and LMWH groups. The antithrombotic effect of LMWF may in part be explained by the observed effect on the TF pathway. TF is considered to be a major contributor to blood thrombogenicity in acute coronary syndromes [14, 15, 16] . Indeed, in our model, apoptotic endothelial cells may become procoagulant and promote thrombin generation by exposing phosphatidylserine and activating TF [8, 14, 15] . Moreover, TF expression was significantly lower in the media of denuded arteries in the LMWF group than in the control and LMWH groups. TFPI regulates the extrinsic blood coagulation pathway by factor Xa-dependent inhibition of tissue factor-factor VIIa complexes and thereby modulates thrombus formation [17] . The endothelium is considered as the principal source of TFPI, and we postu- lated that TFPI would be released by intact endothelial cells (i.e. upstream or downstream the lesion site) [18] . We found that plasma TFPI activity was significantly increased in the LMWF group, in keeping with a previous study demonstrating that a 20-kDa fraction of fucoidan induces TFPI release from human endothelial cells in culture, in a time-and concentration-dependent manner [5] . In contrast, we observed no significant release of TFPI in animals treated with LMWH. Sundaram et al. [19] also reported that TFPI release was not increased in rabbits treated with enoxaparin. In our study, TF expression was significantly lower in animals treated with LMWF than in the control group. Fucoidan interferes with selectins which could inhibit binding of platelets and leukocytes to endothelial cells and thus prevent thrombosis. However, as previously reported by Thorlacius et al. [20] with a higher molecular weight fucoidan, the antithrombotic effect of LMWF was not mediated by inhibition of P-selectin, as we observed no significant difference in P-selectin expression among the 3 groups of animals [20] . Moreover, we ruled out a major contribution of leukocytes in our model, as leukocytes were detected in very small numbers in the media of the arteries in the 3 groups. Other properties of LMWF could also be of interest against arterial thrombosis, as these molecules are able to enhance vascular tube formation and to inhibit smooth muscle cell proliferation and neointimal hyperplasia [21] [22] [23] [24] . Moreover, in a rat model of critical hindlimb ischemia, LMWF promoted therapeutic revascularization induced by fibroblast growth factor 2 [25] . 
Anticoagulant Effect and Bleeding Risk of LMWF
LMWF exerts its anticoagulant activity by catalyzing thrombin inhibition, mainly by heparin cofactor II [2] . We confirm that LMWF has low anticoagulant activity, as, contrary to LMWH, it did not increase the thrombin clotting time or anti-Xa activity [6] . No increase in anticoagulant activity was observed after 4 days of LMWF treatment, suggesting no accumulation of LMWF. Moreover, neither bleeding time nor ␥ -thrombin-induced platelet aggregation was altered by LMWF. These results suggest that LMWF has a particularly promising riskbenefit ratio in the treatment of arterial thrombosis.
Study Limitations
Our data were obtained in an experimental model of arterial thrombosis based on in situ induction of endothelial apoptosis, a phenomenon that plays an important role in human thrombotic plaque erosion [8, 26] . Care is needed before extrapolating these results to ruptured thrombotic plaque or to more complex human atherosclerotic disease.
In conclusion, LMWF, a sulfated polysaccharide extracted from brown seaweeds, can effectively prevent arterial thrombosis in a rabbit model while carrying a low risk of bleeding. LMWF is thus a good candidate drug for the treatment of patients with thrombotic disease.
